Vas Narasimhan, Novartis CEO (Akio Kon/Bloomberg via Getty Images)
Novartis showcases Ph3 data for Fabhalta in IgAN as FDA grants priority review
Months after landing the first approval for the rare disease drug Fabhalta, Novartis is on track to potentially expand the label.
The FDA has granted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
